Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
The HCl gas is generated continuously which is absorbed in the water scrubber using a chilled falling film system
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
Subscribe To Our Newsletter & Stay Updated
